-
1 Comment
NextCure, Inc is currently in a long term downtrend where the price is trading 25.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.4.
NextCure, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 41.5% to $-15M since the same quarter in the previous year.
Finally, its free cash flow grew by 32.8% to $-7M since the same quarter in the previous year.
Based on the above factors, NextCure, Inc gets an overall score of 2/5.
| CurrencyCode | USD |
|---|---|
| Exchange | NASDAQ |
| ISIN | US65343E1082 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Market Cap | 42M |
|---|---|
| Beta | 0.07 |
| Target Price | 5.25 |
| PE Ratio | None |
| Dividend Yield | 0.0% |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NXTC using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
